THE IV SALINE SOLUTION SHORTAGE IS STILL IMPACTING PATIENTS ... CANCER SAYS THE SHORTAGE IS LIFE AND DEATH FOR HIM. KCCI’S LAURA TERRELL EXPLAINS WHY. JARED BEECHER IS BATTLING PANCREATIC ...
VYLOY is the first and only CLDN18.2-targeted treatment approved in the U.S. for adults with advanced gastric and gastroesophageal junction cancer whose tumors are CLDN18.2 positive TOKYO, Oct. 18 ...